每经AI快讯，济川药业（SH 600566，收盘价：27.52元）8月23日发布公告称，公司第十届第十六次董 事会会议于2025年8月22日在湖北济川药业股份有限公司办公大楼十楼会议室以现场及通讯表决的方式 召开。会议审议了《关于公司2025年半年度报告全文及摘要的议案》等文件。 每经头条（nbdtoutiao）——汽车涂料龙头"命悬一线"，资金流向成迷，掌控者深藏不露 （记者 张喜威） 2024年1至12月份，济川药业的营业收入构成为：清热解毒类占比33.53%，儿科类占比28.11%，消化类 占比14.41%，其他行业占比9.94%，呼吸类占比8.13%。 ...

Core Viewpoint - New Tian Pharmaceutical continues to face declining performance in the first half of the year, with both revenue and net profit experiencing significant drops, primarily due to rising raw material costs and a noticeable decrease in product sales [2][4]. Financial Performance - The company reported a revenue of approximately 358 million yuan, a year-on-year decrease of 18.88% [4]. - Net profit attributed to shareholders was about 5.77 million yuan, down 80.99% year-on-year [4]. - The sales of gynecological products, which account for over 70% of revenue, fell by 16.61% [4][5]. Product Sales Breakdown - Gynecological products generated approximately 266 million yuan, representing a 16.61% decline [5]. - Urological products saw a revenue drop of 26.8%, totaling around 61 million yuan [5]. - Revenue from heat-clearing and detoxifying products decreased by 23.04%, amounting to approximately 28 million yuan [5]. - Other product categories experienced a 7% increase in revenue, totaling about 3.61 million yuan, but this only accounted for 1.01% of total revenue [4][5]. Cost and Expense Management - Rising raw material prices have been a persistent issue, with raw material costs accounting for 58.35% of total costs in 2023 [7]. - The company has been actively reducing sales expenses, with a 17.79% decrease in 2023 and a 15.06% decrease in 2024 [10]. - In the first half of 2025, sales expenses were approximately 159 million yuan, down 11.61% year-on-year [10]. Regulatory and Ethical Concerns - New Tian Pharmaceutical's subsidiary faced allegations of commercial bribery, which has led to increased scrutiny and pressure on sales strategies [9]. - The company has acknowledged the situation but has not provided detailed public comments on the allegations [9].